Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Sep 1;111(9):6318-6329.
doi: 10.1097/JS9.0000000000002764. Epub 2025 Jun 16.

CXCL13/CXCR5: a new target for pain treatment

Shujun Sun  1   2   3   4 , Yan Sun  1   2   3 , Jiwei Shen  1   2   3 , Zhangyan Mao  1   2   3   4 , Tianhao Zhang  1   2   3 , Yafen Gao  1   2   3 , Dong Yang  1   2   3   4 , Xiangdong Chen  1   2   3 , Guobin Song  1   2   3
Affiliations
Review

CXCL13/CXCR5: a new target for pain treatment

Shujun Sun et al. Int J Surg. .

Abstract

Pain is a significant global health burden, and current treatments often fail to provide adequate relief due to an incomplete understanding of its mechanisms. This review integrates emerging evidence highlighting the CXCL13/CXCR5 chemokine pathway as a crucial mediator across various pain states, including nociceptive, inflammatory, and neuropathic pain. CXCL13 and CXCR5 are substantially upregulated in pain-related regions such as the spinal cord, dorsal root ganglia (DRG), and cerebrospinal fluid following nerve injury, inflammation, and in conditions like bone cancer or diabetes. The key mechanisms through which they contribute to pain include enhancing neuronal excitability by increasing Nav1.8 sodium channel currents in DRG neurons via p38 MAPK signaling, promoting neuroinflammation by activating NF-κB, ERK, and JNK pathways, which drive the production of pro-inflammatory cytokines (e.g., TNF-α, IL-6, IL-1β) and immune cell infiltration, and activating glial cells, where CXCL13/CXCR5 signaling promotes astrocyte reactivity and indirectly activates microglia, thereby amplifying central sensitization. Genetic knockdown or pharmacological inhibition of CXCL13/CXCR5 has been shown to significantly reduce pain hypersensitivity in preclinical models. The pathway's high tissue specificity in pain pathways and its multifaceted regulation of pain mechanisms make it a promising novel therapeutic target. Future research should address CXCL13/CXCR5 interactions with other pain-related pathways (e.g., CXCL12/CXCR4), explore non-GPCR signaling (e.g., β-arrestins), and validate its potential as a clinical biomarker to guide targeted analgesic development.

Keywords: CXCL13/CXCR5 pathway; glial cell; neuroinflammation; neuronal excitability; pain.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interests. There are no relevant financial or personal relationships that could inappropriately influence or bias the work presented in the manuscript. Examples such as employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding that could be perceived as conflicts of interest are not applicable in this case.

Figures

Figure 1.
Figure 1.
Schematic representation of CXCL13/CXCR5 pathway involving in different pain models through distinct mechanisms.
Figure 2.
Figure 2.
Schematic representation of the CXCL13/CXCR5 pathway in mediating of pain.
Figure 3.
Figure 3.
Schematic representation of Nav1.8 channel contributing to neuronal hyperexcitability and pain hypersensitivity via CXCL13/CXCR5 pathway.
Figure 4.
Figure 4.
Schematic representation of the activation of NF-κB contributing to neuroinflammation via CXCL13/CXCR5 pathway in DRG sensory neurons after sciatic nerve.
Figure 5.
Figure 5.
Schematic representation of spinal neuronal-glial interaction contributing to neuropathic pain after SNL via CXCL13/CXCR5 pathway.
See this image and copyright information in PMC

References

    1. Raja SN, Carr DB, Cohen M, et al. The revised international association for the study of pain definition of pain: concepts, challenges, and compromises. Pain 2020;161:1976–82. - PMC - PubMed
    1. Bushnell MC, Ceko M, low LA. Cognitive and emotional control of pain and its disruption in chronic pain. Nat Rev Neurosci 2013;14:502–11. - PMC - PubMed
    1. Cohen SP, Vase L, Hooten WM. Chronic pain: an update on burden, best practices, and new advances. Lancet Lond Engl 2021;397:2082–97. - PubMed
    1. Cj W. What is this thing called pain? J Clin Invest 2010;120:3742–44. - PMC - PubMed
    1. Rot A, von Andrian UH. Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu Rev Immunol 2004;22:891–928. - PubMed